• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $EMBC

    Embecta Corp.

    Subscribe to $EMBC
    $EMBC
    Medical/Dental Instruments
    Health Care

    Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.

    IPO Year:

    Exchange: NASDAQ

    Website: https://www.embecta.com

    Recent Analyst Ratings for Embecta Corp.

    DatePrice TargetRatingAnalyst
    4/10/2025$15.00Neutral
    Mizuho
    12/2/2024$13.00 → $20.00Underweight → Equal-Weight
    Morgan Stanley
    11/27/2024$26.00Neutral → Buy
    BTIG Research
    10/20/2023Peer Perform
    Wolfe Research
    1/6/2023$28.00Equal-Weight → Underweight
    Morgan Stanley
    9/8/2022Neutral
    BTIG Research
    8/1/2022$33.00Equal-Weight
    Morgan Stanley
    6/21/2022$25.00Underperform
    BofA Securities
    See more ratings

    Embecta Corp. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Embecta Corp.

      SC 13G/A - Embecta Corp. (0001872789) (Subject)

      11/8/24 10:57:43 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Embecta Corp.

      SC 13G/A - Embecta Corp. (0001872789) (Subject)

      11/7/24 4:21:15 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Embecta Corp.

      SC 13G - Embecta Corp. (0001872789) (Subject)

      10/25/24 5:45:30 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Embecta Corp. (Amendment)

      SC 13G/A - Embecta Corp. (0001872789) (Subject)

      2/14/24 10:04:43 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Embecta Corp. (Amendment)

      SC 13G/A - Embecta Corp. (0001872789) (Subject)

      2/13/24 5:04:31 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Embecta Corp.

      SC 13G - Embecta Corp. (0001872789) (Subject)

      2/12/24 12:23:47 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Embecta Corp. (Amendment)

      SC 13G/A - Embecta Corp. (0001872789) (Subject)

      2/9/24 9:03:06 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Embecta Corp.

      SC 13G - Embecta Corp. (0001872789) (Subject)

      1/30/24 12:44:13 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Embecta Corp. (Amendment)

      SC 13G/A - Embecta Corp. (0001872789) (Subject)

      1/23/24 10:44:44 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Embecta Corp. (Amendment)

      SC 13G/A - Embecta Corp. (0001872789) (Subject)

      1/22/24 4:07:42 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care

    Embecta Corp. Financials

    Live finance-specific insights

    See more
    • Embecta Corp. Reports Second Quarter Fiscal 2025 Financial Results

      PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (NASDAQ:EMBC), a global diabetes care company, today reported financial results for the three and six month periods ended March 31, 2025. "This quarter's financial results were once again slightly ahead of our prior expectations, as our teams executed well, which included driving an acceleration in our free-cash flow generation, thereby allowing us to continue to repay debt and create additional balance sheet flexibility," said Devdatt (Dev) Kurdikar, President and Chief Executive Officer of embecta. Mr. Kurdikar added, "In this challenging operating environment, we are raising key profitability

      5/9/25 6:30:00 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • embecta Announces Quarterly Cash Dividend

      PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on June 13, 2025 to stockholders of record at the close of business on May 28, 2025. About embectaembecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on

      5/9/25 6:00:00 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • embecta to Report Fiscal Second Quarter 2025 Financial Results

      PARSIPPANY, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal second quarter 2025 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Friday, May 9, 2025. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the call will be available beginning at 11:00 a.m. ET on May 9, 2025, via the embecta investor re

      4/21/25 5:00:00 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Embecta Corp. Reports First Quarter Fiscal 2025 Financial Results

      PARSIPPANY, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (NASDAQ:EMBC), a global diabetes care company, today reported financial results for the three month period ended December 31, 2024. "Building on our momentum from 2024, embecta began the year with solid performance," said Devdatt (Dev) Kurdikar, Chief Executive Officer of embecta. "We remain on track to complete the restructuring plan associated with the discontinuation of the insulin patch pump program by the end of the first half of the fiscal year and are preparing to launch our brand transition plan in the second half, beginning in the U.S. and Canada. Additionally, we continue to make progr

      2/6/25 6:30:00 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • embecta Announces Quarterly Cash Dividend

      PARSIPPANY, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on March 14, 2025 to stockholders of record at the close of business on February 28, 2025. About embectaembecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channe

      2/6/25 6:00:00 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • embecta to Report Fiscal First Quarter 2025 Financial Results

      PARSIPPANY, N.J., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal first quarter 2025 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Thursday, February 6, 2025. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the call will be available beginning at 11:00 a.m. ET on February 6, 2025, via the embec

      1/23/25 5:00:00 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Embecta Corp. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results; Provides Initial Fiscal Year 2025 Financial Guidance; Discontinues Insulin Patch Pump Program; and Announces Restructuring to Streamline Operations and Reduce Costs

      PARSIPPANY, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (NASDAQ:EMBC), a global diabetes care company, today reported financial results for the three- and twelve-month periods ended September 30, 2024. "We are pleased to report a strong fourth quarter and end to our fiscal year, as we once again delivered results that exceeded our expectations across key financial metrics. We continued to execute on our strategic priorities, and to date, our significant accomplishments include the successful transition of approximately 98% of our revenue to our own ERP system, shared service capabilities, and distribution infrastructure, with India remaining as o

      11/26/24 6:30:00 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • embecta Announces Quarterly Cash Dividend

      PARSIPPANY, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on December 18, 2024 to stockholders of record at the close of business on December 6, 2024. About embectaembecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels

      11/26/24 6:00:00 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • UPDATE - embecta to Report Fiscal Fourth Quarter and Full Year 2024 Financial Results

      PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal fourth quarter and full year 2024 financial results, and provide an operational update, including preliminary fiscal year 2025 financial guidance, at 8:00 a.m. Eastern Time (ET) on Tuesday, November 26, 2024. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the call will be available beginning at 11:00 a.m. ET

      11/12/24 5:31:55 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • embecta to Report Fiscal Fourth Quarter and Full Year 2024 Financial Results

      PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal fourth quarter and full year 2024 financial results, and provide an operational update, including preliminary fiscal year 2025 financial guidance, at 8:00 a.m. Eastern Time (ET) on Thursday, November 26, 2024. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the call will be available beginning at 11:00 a.m. ET

      11/12/24 5:00:00 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care

    Embecta Corp. SEC Filings

    See more
    • SEC Form 10-Q filed by Embecta Corp.

      10-Q - Embecta Corp. (0001872789) (Filer)

      5/9/25 11:45:56 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Embecta Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Embecta Corp. (0001872789) (Filer)

      5/9/25 6:56:44 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Embecta Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Embecta Corp. (0001872789) (Filer)

      2/14/25 4:30:30 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • SEC Form 144 filed by Embecta Corp.

      144 - Embecta Corp. (0001872789) (Subject)

      2/13/25 3:57:05 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Embecta Corp.

      10-Q - Embecta Corp. (0001872789) (Filer)

      2/6/25 12:25:50 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Embecta Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Embecta Corp. (0001872789) (Filer)

      2/6/25 7:00:45 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Embecta Corp.

      DEFA14A - Embecta Corp. (0001872789) (Filer)

      12/19/24 4:18:21 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by Embecta Corp.

      DEF 14A - Embecta Corp. (0001872789) (Filer)

      12/19/24 4:17:34 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-K filed by Embecta Corp.

      10-K - Embecta Corp. (0001872789) (Filer)

      12/11/24 4:52:35 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Embecta Corp. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Embecta Corp. (0001872789) (Filer)

      12/2/24 4:43:24 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care

    Embecta Corp. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP and CFO Elguicze Jacob covered exercise/tax liability with 4,948 shares, decreasing direct ownership by 3% to 168,599 units (SEC Form 4)

      4 - Embecta Corp. (0001872789) (Issuer)

      4/8/25 4:25:00 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • SVP, Global Manuf./Sup. Chain Curtis Shaun covered exercise/tax liability with 3,249 shares, decreasing direct ownership by 5% to 59,061 units (SEC Form 4)

      4 - Embecta Corp. (0001872789) (Issuer)

      4/8/25 4:22:22 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • SVP, GC, Head Corp. Dev., Secy Mann Jeffrey Z covered exercise/tax liability with 5,285 shares, decreasing direct ownership by 4% to 139,439 units (SEC Form 4)

      4 - Embecta Corp. (0001872789) (Issuer)

      4/8/25 4:20:11 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • President and CEO Kurdikar Devdatt covered exercise/tax liability with 39,592 shares, decreasing direct ownership by 7% to 499,582 units (SEC Form 4)

      4 - Embecta Corp. (0001872789) (Issuer)

      4/8/25 4:16:48 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Director Melcher David F bought $177,646 worth of shares (13,000 units at $13.67), increasing direct ownership by 20% to 76,681 units (SEC Form 4)

      4 - Embecta Corp. (0001872789) (Issuer)

      2/25/25 4:26:16 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Director Morris Milton Mayo was granted 13,839 shares and sold $50,783 worth of shares (3,100 units at $16.38), increasing direct ownership by 42% to 36,133 units (SEC Form 4)

      4 - Embecta Corp. (0001872789) (Issuer)

      2/14/25 6:42:36 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Director Albritton David was granted 13,839 shares, increasing direct ownership by 53% to 39,743 units (SEC Form 4)

      4 - Embecta Corp. (0001872789) (Issuer)

      2/14/25 6:36:37 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Director Anderson Carrie L was granted 13,839 shares, increasing direct ownership by 53% to 39,743 units (SEC Form 4)

      4 - Embecta Corp. (0001872789) (Issuer)

      2/14/25 6:30:39 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Director Prange Karen was granted 13,839 shares, increasing direct ownership by 53% to 39,743 units (SEC Form 4)

      4 - Embecta Corp. (0001872789) (Issuer)

      2/14/25 6:26:32 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Director Reidy Christopher R was granted 13,839 shares, increasing direct ownership by 44% to 45,284 units (SEC Form 4)

      4 - Embecta Corp. (0001872789) (Issuer)

      2/14/25 6:21:50 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care

    Embecta Corp. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on Embecta Corp. with a new price target

      Mizuho initiated coverage of Embecta Corp. with a rating of Neutral and set a new price target of $15.00

      4/10/25 12:41:09 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Embecta Corp. upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Embecta Corp. from Underweight to Equal-Weight and set a new price target of $20.00 from $13.00 previously

      12/2/24 6:56:10 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Embecta Corp. upgraded by BTIG Research with a new price target

      BTIG Research upgraded Embecta Corp. from Neutral to Buy and set a new price target of $26.00

      11/27/24 7:22:14 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Wolfe Research initiated coverage on Embecta Corp.

      Wolfe Research initiated coverage of Embecta Corp. with a rating of Peer Perform

      10/20/23 8:03:46 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Embecta Corp. downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Embecta Corp. from Equal-Weight to Underweight and set a new price target of $28.00

      1/6/23 7:34:26 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • BTIG Research initiated coverage on Embecta Corp.

      BTIG Research initiated coverage of Embecta Corp. with a rating of Neutral

      9/8/22 7:46:07 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Morgan Stanley initiated coverage on Embecta Corp. with a new price target

      Morgan Stanley initiated coverage of Embecta Corp. with a rating of Equal-Weight and set a new price target of $33.00

      8/1/22 9:07:28 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • BofA Securities initiated coverage on Embecta Corp. with a new price target

      BofA Securities initiated coverage of Embecta Corp. with a rating of Underperform and set a new price target of $25.00

      6/21/22 7:46:53 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care

    Embecta Corp. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Embecta Corp. Reports Second Quarter Fiscal 2025 Financial Results

      PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (NASDAQ:EMBC), a global diabetes care company, today reported financial results for the three and six month periods ended March 31, 2025. "This quarter's financial results were once again slightly ahead of our prior expectations, as our teams executed well, which included driving an acceleration in our free-cash flow generation, thereby allowing us to continue to repay debt and create additional balance sheet flexibility," said Devdatt (Dev) Kurdikar, President and Chief Executive Officer of embecta. Mr. Kurdikar added, "In this challenging operating environment, we are raising key profitability

      5/9/25 6:30:00 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • embecta Announces Quarterly Cash Dividend

      PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on June 13, 2025 to stockholders of record at the close of business on May 28, 2025. About embectaembecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on

      5/9/25 6:00:00 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Embecta to host Analyst and Investor Day on May 22, 2025

      PARSIPPANY, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will hold an Analyst and Investor Day on May 22, 2025, from 9:00 a.m. to 12:30 p.m. in New York City. Dev Kurdikar, President & Chief Executive Officer, and Jake Elguicze, Chief Financial Officer, will be joined by members of the embecta leadership team to present strategic and business overview, including value creation opportunities, the company's financial profile and its long-term objectives. To register for the webcast, please go to: embecta Analyst & Investor Day Webcast Registration. Visit InvestorDay.embecta.com

      4/28/25 7:30:00 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • embecta to Report Fiscal Second Quarter 2025 Financial Results

      PARSIPPANY, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal second quarter 2025 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Friday, May 9, 2025. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the call will be available beginning at 11:00 a.m. ET on May 9, 2025, via the embecta investor re

      4/21/25 5:00:00 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Mayo Clinic Proceedings Publishes New Global Insulin Injection Recommendations

      PARSIPPANY, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced a new landmark publication in the Mayo Clinic Proceedings. The publication introduces the FITTER Forward Expert Recommendations, an updated set of global best practices for insulin injection technique and education. Authored by a panel of 16 diabetes specialists from 13 countries, the FITTER Forward initiative highlights the critical need for improved training and standardization in insulin delivery, aiming to enhance clinical outcomes for millions of people with diabetes worldwide. "When physicians and nur

      4/1/25 8:05:00 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

      3/11/25 7:05:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities
    • Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of

      3/11/25 7:00:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities
    • embecta to Participate at the J.P. Morgan Global Leveraged Finance Conference

      PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (NASDAQ:EMBC) today announced that Jake Elguicze, embecta's Chief Financial Officer, will present at the J.P. Morgan Global Leveraged Finance Conference in Miami on Tuesday, February 25, 2025 at 3:00 p.m. ET. About embectaembecta is a global diabetes care company that is leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, and Instagram. Contacts:  Media

      2/18/25 5:00:00 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Embecta Corp. Reports First Quarter Fiscal 2025 Financial Results

      PARSIPPANY, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (NASDAQ:EMBC), a global diabetes care company, today reported financial results for the three month period ended December 31, 2024. "Building on our momentum from 2024, embecta began the year with solid performance," said Devdatt (Dev) Kurdikar, Chief Executive Officer of embecta. "We remain on track to complete the restructuring plan associated with the discontinuation of the insulin patch pump program by the end of the first half of the fiscal year and are preparing to launch our brand transition plan in the second half, beginning in the U.S. and Canada. Additionally, we continue to make progr

      2/6/25 6:30:00 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • embecta Announces Quarterly Cash Dividend

      PARSIPPANY, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on March 14, 2025 to stockholders of record at the close of business on February 28, 2025. About embectaembecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channe

      2/6/25 6:00:00 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care

    Embecta Corp. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Melcher David F bought $177,646 worth of shares (13,000 units at $13.67), increasing direct ownership by 20% to 76,681 units (SEC Form 4)

      4 - Embecta Corp. (0001872789) (Issuer)

      2/25/25 4:26:16 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Melcher David F bought $32,500 worth of shares (2,000 units at $16.25), increasing direct ownership by 5% to 45,080 units (SEC Form 4)

      4 - Embecta Corp. (0001872789) (Issuer)

      2/12/24 7:08:59 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care

    Embecta Corp. Leadership Updates

    Live Leadership Updates

    See more
    • PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

      3/11/25 7:05:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities
    • Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of

      3/11/25 7:00:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities
    • Zimmer Biomet Announces Appointment of Devdatt Kurdikar to Board of Directors

      WARSAW, Ind., June 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Devdatt "Dev" Kurdikar, President, Chief Executive Officer and a member of the board of directors of Embecta Corp. (embecta), has been appointed to the Zimmer Biomet Board, effective immediately. embecta (NASDAQ:EMBC), formerly part of Becton, Dickinson and Company (BD), is one of the largest pure-play diabetes management companies in the world.  "We are pleased to welcome Dev to the ZB Board," said Chris Begley, Chairman of the

      6/20/24 7:30:00 AM ET
      $EMBC
      $ZBH
      Medical/Dental Instruments
      Health Care
      Industrial Specialties
    • Revelyst Announces Chief Supply Chain Officer

      Revelyst is thrilled to appoint longtime supply chain and business operations leader Joe Beck to the position of Chief Supply Chain Officer. Revelyst, a collective of world-class maker brands that design and manufacture performance gear and precision technologies and a segment of Vista Outdoor Inc. (NYSE:VSTO), today announced the appointment of Joe Beck as Chief Supply Chain Officer, effective April 22. In the third quarter, Revelyst launched GEAR Up, the company's plan to simplify its business model, deliver increased efficiency and profitability, and reinvest in its highest potential brands to accelerate growth and transformation. The appointment of a seasoned, transformational supply

      4/23/24 7:00:00 AM ET
      $BDX
      $EMBC
      $VSTO
      Medical/Dental Instruments
      Health Care
      Ordnance And Accessories
      Industrials
    • embecta to Recognize National Diabetes Awareness Month by Ringing Nasdaq Opening Bell

      PARSIPPANY, N.J., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company, announced it will ring the Nasdaq opening bell today, in recognition of National Diabetes Awareness Month in November. The coming year is also a time to celebrate the company's heritage in providing solutions to people living with diabetes, including 100 years since the development and launch of the first syringe dedicated to insulin delivery. Advocacy and professional groups including the Association of Diabetes Care & Education Specialists (ADCES), Beyond Type 1, Beyond Type 2, Camp Nejeda, Children with Diabetes, Diabetes Education and Camping Association (DECA),

      10/31/23 6:50:00 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Campbell Appoints Carrie Anderson Chief Financial Officer

      Campbell Soup Company (NYSE:CPB) today announced the appointment of Carrie L. Anderson as Executive Vice President and Chief Financial Officer, effective Feb. 6. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230125005725/en/Carrie Anderson (Photo: Business Wire) Anderson will lead Campbell's finance function, including controllership, corporate financial planning and analysis, corporate strategy and development, tax, treasury, internal audit, investor relations, transactional services and financial systems. She will report to Campbell's President and Chief Executive Officer Mark Clouse and become a member of the company's Operat

      1/25/23 4:30:00 PM ET
      $CPB
      $EMBC
      $IART
      Packaged Foods
      Consumer Staples
      Medical/Dental Instruments
      Health Care
    • Nordson Corporation Appoints Milton Morris to Board of Directors

      Nordson Corporation (NASDAQ:NDSN) announced the appointment of Dr. Milton Morris, recently retired president and chief executive officer of Neuspera Medical, Inc., to its board of directors. Dr. Morris will bring robust business leadership experience, as well as a legacy of successful product innovation, to the board. "We are pleased to welcome Milton as a new independent director. His passion for innovation and new product development aligns well with Nordson's strength of understanding customer needs and bringing diversified precision technology solutions to market. In addition, his professional background in medical devices will enhance our understanding, as Nordson plans to further exp

      9/15/22 4:30:00 PM ET
      $BSX
      $EMBC
      $MYO
      $NDSN
      Medical/Dental Instruments
      Health Care
      Industrial Specialties
      Industrial Machinery/Components